Patents Examined by Valarie Bertoglio
  • Patent number: 10214727
    Abstract: Methods of preparing platelet-rich plasma (PRP) compositions are disclosed which include adding CD34+ cells to the PRP composition. In addition, the concentration of stromal-derived factor-1 (SDF-1) in the PRP composition may be adjusted to a pre-determined value. The compositions may have elevated levels of white blood cells but reduced levels of neutrophils. Compositions produced by the method are also disclosed.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: February 26, 2019
    Inventor: Allan Mishra
  • Patent number: 9833496
    Abstract: The invention relates to the fields of biochemistry, pharmacy and oncology. The invention particularly relates to the use of novel stem cell markers for the isolation of stem cells. The invention further relates to the obtained stem cells and their use in for example research or treatment, for example, for the preparation of a medicament for the treatment of damaged or diseased tissue. In one of the embodiments, the invention provides a method for obtaining (or isolating) stem cells comprising optionally preparing a cell suspension from a tissue or organ sample, contacting said cell suspension with an Lgr 6 or 5 binding compound, identify the cells bound to said binding compound, and optionally isolating the stem cells from said binding compound. The invention further relates to means suitable for cancer treatment and even more specific for the treatment of cancer by eradicating cancer stem cells.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: December 5, 2017
    Assignee: Koninklijke Nederlandse Akademie van Wetenschappen
    Inventors: Johannes C. Clevers, Nicholas Barker, Andrea Haegebarth, Marcus Lambertus Van de Wetering
  • Patent number: 9828630
    Abstract: The present disclosure relates to the use of laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. Methods of enhancing genetic diagnosis by expanding a single stem cell on laminin-521 prior to PCR amplification are disclosed herein.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: November 28, 2017
    Assignee: BIOLAMINA AB
    Inventors: Karl Tryggvason, Kristian Tryggvason
  • Patent number: 9822160
    Abstract: The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: November 21, 2017
    Assignee: Corning Incorporated
    Inventors: Na Li, Jie Wang, Christopher J. Patten
  • Patent number: 9783779
    Abstract: The present invention provides novel methods for improving the efficiency of artificial activation of unfertilized mammalian oocytes by reducing the intracellular concentration of Zn2+ in the oocyte. The methods of the invention may additionally comprise a preceding step of increasing the intracellular concentration of Ca2+ in the oocyte prior to reduction of the intracellular Zn2+ concentration. The invention further provides unfertilized oocytes activated by the disclosed methods and viable mammalian animals produced from unfertilized oocytes activated by the disclosed methods.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: October 10, 2017
    Assignee: The Curators of the University of Missouri
    Inventors: Kiho Lee, Randall S. Prather
  • Patent number: 9771559
    Abstract: The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: September 26, 2017
    Assignee: Stowers Institute for Medical Research
    Inventors: John M. Perry, Linheng Li, Justin C. Grindley
  • Patent number: 9771560
    Abstract: Disclosed are methods of inducing differentiation of stem into myogenic cells without gene manipulation and for inducing proliferation of satellite cells. The cells can be used as a source of cells for transplantation in a subject in need thereof. Also disclosed is a screening assay for screening test compounds using blastomere cultures.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 26, 2017
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, JOSLIN DIABETES CENTER INC.
    Inventors: Leonard I. Zon, Cong Xu, Amy J. Wagers, C. Ronald Kahn
  • Patent number: 9771409
    Abstract: The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: September 26, 2017
    Assignee: Corning Incorporated
    Inventors: Na Li, Jie Wang, Christopher J. Patten
  • Patent number: 9763432
    Abstract: The present invention relates to the method and use of reef coral fluorescent proteins in making transgenic red, green and yellow fluorescent zebrafish. Preferably, such fluorescent zebrafish are fertile and used to establish a population of transgenic zebrafish and to provide to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: September 19, 2017
    Assignee: GLOFISH LLC
    Inventors: Alan Blake, Richard Crockett, Jeffrey Essner, Perry Hackett, Aidas Nasevicius
  • Patent number: 9763430
    Abstract: Four zebrafish gene promoters, which are skin specific, muscle specific, skeletal muscle specific and ubiquitously expressed respectively, were isolated and ligated to the 5? end of the EGFP gene. When the resulting chimeric gene constructs were introduced into zebrafish, the transgenic zebrafish emit green fluorescence under a blue light or ultraviolet light according to the specificity of the promoters used. Thus, new varieties of ornamental fish of different fluorescence patterns, e.g., skin fluorescence, muscle fluorescence, skeletal muscle-specific and/or ubiquitous fluorescence, are developed.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: September 19, 2017
    Assignee: National University of Singapore
    Inventors: Zhiyuan Gong, Jiangyan He, Bensheng Ju, Toong Jin Lam, Yanfei Xu, Tie Yan
  • Patent number: 9752125
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells expressing markers characteristic of the pancreatic endoderm lineage, wherein greater than 50% of the cells in the population co-express PDX1 and NKX6.1.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: September 5, 2017
    Assignee: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • Patent number: 9745598
    Abstract: Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3?-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: August 29, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, David Jonathan Heslin, Ka-Man Venus Lai, David M. Valenzuela
  • Patent number: 9745550
    Abstract: Synthetic surfaces suitable for culturing stem cell derived cardiomyocytes contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived cardiomyocytes in chemically defined media.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: August 29, 2017
    Assignee: Asterias Biotherapeutics, Inc.
    Inventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger
  • Patent number: 9725737
    Abstract: Disclosed is a cell which enables the reproduction of a cartilage tissue and has a proliferative ability. Also disclosed is a technique for providing a cell supply source which can be used in a definitive treatment of osteochondrosis deformans. A chondrocyte-like cell which has the same properties as those of a chondrocyte and can proliferate can be produced by selecting a combination of an Myc family gene and/or a Klf family gene and a SOX9 gene and introducing the combination into a somatic cell. The chondrocyte-like cell can be used for a medical purpose of cartilage regeneration.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: August 8, 2017
    Assignee: IPS ACADEMIA JAPAN, INC.
    Inventor: Noriyuki Tsumaki
  • Patent number: 9725697
    Abstract: The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: August 8, 2017
    Assignee: The University Court of The University of Edinburgh
    Inventors: Brendon Stewart Noble, David Matthew Pier
  • Patent number: 9714278
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: July 25, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Sonia Guedan Carrio, Yangbing Zhao, John Scholler
  • Patent number: 9713628
    Abstract: Restoration or increase of inhibitory interneuron function in vivo is achieved by transplantation of MGE cells into the brain. Compositions containing MGE cells are provided as are uses to treat various diseases characterized by abnormal inhibitory interneuron function or in cases where increase inhibition may ameliorate neural circuits that are abnormally activated.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: July 25, 2017
    Assignee: The Regents of the University of California
    Inventors: Scott C. Baraban, John L. Rubenstein, Arturo Alvarez-Buylla
  • Patent number: 9695445
    Abstract: An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: July 4, 2017
    Assignee: ID Pharma Co., Ltd.
    Inventors: Noemi Fusaki, Hiroshi Ban, Mamoru Hasegawa, Yoshikazu Yonemitsu
  • Patent number: 9682107
    Abstract: The invention generally relates to postnatal dental stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal dental pulp stem cells, use of the cells to generate dentin, and differentiation of the cells. In another aspect, the invention relates to human postnatal deciduous dental pulp multipotent stem cells, use of the cells to generate dentin, and differentiation of the cells.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: June 20, 2017
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Songtao Shi, Pamela Gehron Robey, Stan Gronthos, Masako Miura
  • Patent number: 9677051
    Abstract: This invention provides method and media suitable for inducing and supporting the differentiation of stem cells into erythroid cells.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: June 13, 2017
    Assignees: The Common Services Agency, University Court of the University of Glasgow
    Inventors: Joanne Mountford, Emmanuel Oliver